Daily spirometry in an acute exacerbation of adult cystic fibrosis patients-Reference-Cited by-同舟云学术

Daily spirometry in an acute exacerbation of adult cystic fibrosis patients

Published:2017-11-28 Issue:3 Volume:15 Page:258-264
ISSN:1479-9731
Container-title:Chronic Respiratory Disease
language:en
Short-container-title:Chron Respir Dis

Author:

Stephen Michael J¹,Long Alex²,Bonsall Chad³,Hoag Jeffrey B¹,Shah Smita⁴,Bisberg Dorothy⁴,Holsclaw Douglas³,Varlotta Laurie⁵,Fiel Stan⁶,Du Doantrang⁷,Zanni Robert⁷,Hadjiliadis Denis³

Affiliation:

1. Division of Pulmonary and Critical Care, Drexel University School of Medicine, Philadelphia, PA, USA

2. Drexel University School of Public Health, Philadelphia, PA, USA

3. Division of Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA, USA

4. Barnabas Health Medical Group, Saint Barnabas Medical Center, Pediatric Specialty Center, West Orange, NJ, USA

5. St Chrisophter’s Hospital for Children, Philadelphia, PA, USA

6. Atlantic Health System, Morristown, NJ, USA

7. Monmouth Medical Center, Long Branch, NJ, USA

Abstract

To help answer the question of length of intravenous antibiotics during an acute exacerbation of cystic fibrosis (CF), we had subjects to follow daily home spirometry while on intravenous antibiotics. CF patients, 18 and older, with an acute exacerbation requiring intravenous antibiotics had a daily FEV1. The average time to a 10% increase over their initial sick FEV1 was calculated, as well as the time to a new baseline. A total of 25 subjects completed the study. Ten of the 25 subjects did not have a sustainable 10% increase in FEV1. Of the 15 subjects with a sustainable 10% increase in FEV1, it took 5.2 days (±4.5) after day 1, while a new baseline was achieved on average at 6.6 days (±4.8) after day 1. Given the wide range of time to a 10% improvement and new baseline, it is recommended there should be flexibility in length of intravenous antibiotics in CF, not by a preset number.

Publisher

SAGE Publications

Subject

Pulmonary and Respiratory Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1479972317743756

Reference22 articles.

1. Developing Cystic Fibrosis Lung Transplant Referral Criteria Using Predictors of 2-Year Mortality

2. Predictive 5-Year Survivorship Model of Cystic Fibrosis

3. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis

4. The Cost of Medical Care for Patients With Cystic Fibrosis in a Health Maintenance Organization

5. Quality of life in young people with cystic fibrosis: effects of hospitalization, age and gender, and differences in parent/child perceptions

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Home‐spirometry exacerbation profiles in children with cystic fibrosis;Pediatric Pulmonology;2023-11-28

2. Evaluation of rescue oral glucocorticoid therapy during inpatient cystic fibrosis exacerbations;Pediatric Pulmonology;2020-12-14

3. Neutrophil count in sputum is associated with increased sputum glucose and sputum L-lactate in cystic fibrosis;PLOS ONE;2020-09-11

4. Disadvantages of set length antibiotic treatment for pulmonary exacerbation;The Lancet Respiratory Medicine;2018-08